FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182118538> ?p ?o ?g. }

• W3182118538 endingPage "394" @default.
• W3182118538 startingPage "394" @default.
• W3182118538 abstract "Abstract Background: NTRK gene fusions are oncogenic drivers in various tumor types. Overall survival (OS) of patients (pts) with tumors harboring NTRK fusions compared to pts without is unknown, and data on co-occurrence of NTRK fusions with other oncogenic drivers are limited.1 Methods: This retrospective study used genomic data generated by the 100,000 Genomes Project with linked clinical data from UK cancer databases. Pts with cancer who had undergone tumor whole genome sequencing between Mar 2016 and Jul 2019 were included. OS of pts with and without NTRK fusions, matched by exact and distance matching with a 1:4 NTRK+:NTRK− ratio, was analyzed by Kaplan-Meier method and Cox regression. Key alterations in ALK, BRAF, EGFR, HER2, KRAS and ROS1, and tumor mutation burden (TMB) and microsatellite instability (MSI), were evaluated along with NTRK gene fusions. Results: Of 15,223 pts analyzed, 38 (0.2%) had NTRK fusions, identified in 11 cancers (Genomics England classification), the most common being breast cancer (n=9), colorectal cancer (CRC; n=9), and sarcoma (n=7). While there was no significant OS difference in pts with and without NTRK fusions, the HR was 1.47 (95% CI 0.39-5.57; Table). Of the tested oncogenic drivers, only KRAS mutation was identified in 2 (5%) pts with an NTRK fusion (both hepatobiliary cancer), while oncogenic driver frequency in pts without NTRK fusions ranged from 0.1-11.6%. High TMB was more common in pts with NTRK fusions than in those without (21% vs 6%), as was high MSI (18% vs 6%); all pts with NTRK fusions and high TMB and/or MSI had CRC. Conclusions: While no statistical difference in OS was observed, there was a trend to higher risk of death in pts with NTRK fusions compared to those without, consistent with a recent US study.1 Co-occurrence of NTRK fusions and other biomarkers was rare, except for high TMB and high MSI in CRC. These results highlight NTRK fusions as actionable biomarkers and emphasize the need for NTRK gene fusion testing. NTRK− (n=72†)NTRK+ (n=18†)Median follow-up (IQR), years2.28 (1.57-2.98)2.01 (1.40-2.97)Median OS (IQR), yearsNE (NE-NE)NE (NE-NE)Landmark OS, % (95% CI)1 year96 (91-100)94 (84-100)2 years94 (89-100)87 (71-100)3 years88 (78-99)87 (71-100)HR (95% CI)1.47 (0.39-5.57)†Only patients with linked clinical data and who were matched were included in the OS analysis.1CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NE, not estimable; NTRK; neurotrophic tyrosine receptor kinase; OS, overall survival.1. Bazhenova L, et al. Clin Cancer Res. 2020;26(12 Suppl 1):09-09. Citation Format: John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt Schmitz, Jihong Zong, John A. Reeves, Karen Keating, Amanda Bruno, Marc Fellous, Lyudmila Bazhenova. Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 394." @default.
• W3182118538 created "2021-07-19" @default.
• W3182118538 creator A5005261702 @default.
• W3182118538 creator A5014832537 @default.
• W3182118538 creator A5016610225 @default.
• W3182118538 creator A5017763726 @default.
• W3182118538 creator A5031571336 @default.
• W3182118538 creator A5038774978 @default.
• W3182118538 creator A5065216782 @default.
• W3182118538 creator A5071438959 @default.
• W3182118538 creator A5073411202 @default.
• W3182118538 creator A5079347473 @default.
• W3182118538 creator A5083898918 @default.
• W3182118538 creator A5087896256 @default.
• W3182118538 creator A5091729638 @default.
• W3182118538 date "2021-07-01" @default.
• W3182118538 modified "2023-10-09" @default.
• W3182118538 title "Abstract 394: Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project" @default.
• W3182118538 doi "https://doi.org/10.1158/1538-7445.am2021-394" @default.
• W3182118538 hasPublicationYear "2021" @default.
• W3182118538 type Work @default.
• W3182118538 sameAs 3182118538 @default.
• W3182118538 citedByCount "5" @default.
• W3182118538 countsByYear W31821185382021 @default.
• W3182118538 countsByYear W31821185382022 @default.
• W3182118538 countsByYear W31821185382023 @default.
• W3182118538 crossrefType "journal-article" @default.
• W3182118538 hasAuthorship W3182118538A5005261702 @default.
• W3182118538 hasAuthorship W3182118538A5014832537 @default.
• W3182118538 hasAuthorship W3182118538A5016610225 @default.
• W3182118538 hasAuthorship W3182118538A5017763726 @default.
• W3182118538 hasAuthorship W3182118538A5031571336 @default.
• W3182118538 hasAuthorship W3182118538A5038774978 @default.
• W3182118538 hasAuthorship W3182118538A5065216782 @default.
• W3182118538 hasAuthorship W3182118538A5071438959 @default.
• W3182118538 hasAuthorship W3182118538A5073411202 @default.
• W3182118538 hasAuthorship W3182118538A5079347473 @default.
• W3182118538 hasAuthorship W3182118538A5083898918 @default.
• W3182118538 hasAuthorship W3182118538A5087896256 @default.
• W3182118538 hasAuthorship W3182118538A5091729638 @default.
• W3182118538 hasConcept C104317684 @default.
• W3182118538 hasConcept C111829193 @default.
• W3182118538 hasConcept C121608353 @default.
• W3182118538 hasConcept C126322002 @default.
• W3182118538 hasConcept C143998085 @default.
• W3182118538 hasConcept C180754005 @default.
• W3182118538 hasConcept C2775999482 @default.
• W3182118538 hasConcept C2776232967 @default.
• W3182118538 hasConcept C2776256026 @default.
• W3182118538 hasConcept C2779422266 @default.
• W3182118538 hasConcept C2779767149 @default.
• W3182118538 hasConcept C2781182431 @default.
• W3182118538 hasConcept C2781187634 @default.
• W3182118538 hasConcept C502942594 @default.
• W3182118538 hasConcept C526805850 @default.
• W3182118538 hasConcept C54355233 @default.
• W3182118538 hasConcept C61320498 @default.
• W3182118538 hasConcept C71924100 @default.
• W3182118538 hasConcept C86803240 @default.
• W3182118538 hasConceptScore W3182118538C104317684 @default.
• W3182118538 hasConceptScore W3182118538C111829193 @default.
• W3182118538 hasConceptScore W3182118538C121608353 @default.
• W3182118538 hasConceptScore W3182118538C126322002 @default.
• W3182118538 hasConceptScore W3182118538C143998085 @default.
• W3182118538 hasConceptScore W3182118538C180754005 @default.
• W3182118538 hasConceptScore W3182118538C2775999482 @default.
• W3182118538 hasConceptScore W3182118538C2776232967 @default.
• W3182118538 hasConceptScore W3182118538C2776256026 @default.
• W3182118538 hasConceptScore W3182118538C2779422266 @default.
• W3182118538 hasConceptScore W3182118538C2779767149 @default.
• W3182118538 hasConceptScore W3182118538C2781182431 @default.
• W3182118538 hasConceptScore W3182118538C2781187634 @default.
• W3182118538 hasConceptScore W3182118538C502942594 @default.
• W3182118538 hasConceptScore W3182118538C526805850 @default.
• W3182118538 hasConceptScore W3182118538C54355233 @default.
• W3182118538 hasConceptScore W3182118538C61320498 @default.
• W3182118538 hasConceptScore W3182118538C71924100 @default.
• W3182118538 hasConceptScore W3182118538C86803240 @default.
• W3182118538 hasIssue "13_Supplement" @default.
• W3182118538 hasLocation W31821185381 @default.
• W3182118538 hasOpenAccess W3182118538 @default.
• W3182118538 hasPrimaryLocation W31821185381 @default.
• W3182118538 hasRelatedWork W2058644395 @default.
• W3182118538 hasRelatedWork W2640058737 @default.
• W3182118538 hasRelatedWork W2745391639 @default.
• W3182118538 hasRelatedWork W2953666243 @default.
• W3182118538 hasRelatedWork W2961707949 @default.
• W3182118538 hasRelatedWork W2972270404 @default.
• W3182118538 hasRelatedWork W3096306511 @default.
• W3182118538 hasRelatedWork W3201550227 @default.
• W3182118538 hasRelatedWork W3203934256 @default.
• W3182118538 hasRelatedWork W4366597751 @default.
• W3182118538 hasVolume "81" @default.
• W3182118538 isParatext "false" @default.
• W3182118538 isRetracted "false" @default.
• W3182118538 magId "3182118538" @default.
• W3182118538 workType "article" @default.